Home › Compound Library › LSD (Lysergic Acid Diethylamide)

LSD (Lysergic Acid Diethylamide)

Psychedelicoral · inferred

Potent semi-synthetic ergoline psychedelic and 5-HT2A partial agonist. Active at microgram doses. Despite its short plasma half-life (~3.6h), subjective effects last 8-12 hours, likely due to prolonged receptor binding ("lid" trapping). Metabolite O-H-LSD is the primary urinary marker.

Projected serum levels — 1 tabs (≈ 0.10 mg), as needed (shown daily)

LSD (Lysergic Acid Diethylamide)
LSD (Lysergic Acid Diethylamide) modeled serum levels, 1 tabs (≈ 0.10 mg) as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 tabs (≈ 0.10 mg) as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 0.054 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Psychedelic
Route modeled
Oral
Model confidence
inferred
Half-life
3.6 h
Common dose
1 tabs (≈ 0.10 mg)
Reference dose range
0.50–2 tabs (single dose)
Suggested cadence
as needed (shown daily)
Validated against
0.20 mg oral — Cmax 0.004 mg/L at 1.5 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + LSD (Lysergic Acid Diethylamide) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + LSD (Lysergic Acid Diethylamide) Serotonin risk

    25I-NBOMe and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + LSD (Lysergic Acid Diethylamide) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + LSD (Lysergic Acid Diethylamide) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + LSD (Lysergic Acid Diethylamide) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    4-AcO-DMT (Psilacetin) + LSD (Lysergic Acid Diethylamide) Serotonin risk

    4-AcO-DMT (Psilacetin) and LSD (Lysergic Acid Diethylamide) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 205 modeled interaction pairings for lsd (lysergic acid diethylamide) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects Dolder PC et al. · Clinical Pharmacology & Therapeutics, 2017 DOI

    Landmark PK/PD study of 100 and 200 mcg oral LSD showing plasma half-life of 3.6 hours with dose-proportional kinetics and subjective effects lasting 8-12 hours.

  2. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans Dolder PC et al. · International Journal of Neuropsychopharmacology, 2015 DOI

    First modern controlled PK study of LSD showing rapid absorption (Tmax ~1.5h), elimination half-life of 3.6h up to 12h, and prolonged effects beyond plasma elimination due to receptor binding.

  3. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants Holze F et al. · Clinical Pharmacology & Therapeutics, 2021 DOI

    Characterized microdose (5-20 mcg) LSD pharmacokinetics showing elimination half-lives of 2.5-2.9 hours with dose-proportional plasma concentrations.

3 published studies referenced in the app, each with a plain-language summary.